AB-FUBINACA Stats & Data

AB-FUBINACA was initially synthesized by Pfizer in 2009 during research into novel analgesic compounds. The pharmaceutical company never advanced the substance to human clinical trials, and it was subsequently abandoned as a potential medication. The compound first appeared on the recreational drug market in 2012, when Japanese researchers identified it as an active ingredient in synthetic cannabinoid products being sold in that country. It was discovered alongside AB-PINACA, a structurally related compound that had not been previously documented in the scientific literature. AB-FUBINACA subsequently became one of the more prevalent synthetic cannabinoids circulating in recreational drug markets. In August 2018, AB-FUBINACA gained significant public attention following a mass overdose event in New Haven, Connecticut. Beginning on August 15, approximately 70 individuals overdosed in the vicinity of Yale University's campus after consuming adulterated synthetic cannabis products. By the end of that week, over 100 people had required emergency medical transport to local hospitals. Law enforcement subsequently arrested three individuals on charges related to dealing synthetic cannabis products containing AB-FUBINACA.

The toxicity and long-term health effects of recreational AB-FUBINACA use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because AB-FUBINACA has very little history of human usage. Anecdotal evidence from people who have tried AB-FUBINACA within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). Informal experiments have shown that overdose will cause physical discomfort including heart palpitations, vertigo and sedation at much lower than dangerous doses, usually causing the user to suffer large amounts of anxiety or to fall asleep.